David P. Luci

Filings by David P. Luci span 5 companies, the busiest being Bioenvision Inc, Abeona Therapeutics Inc. and Acurx Pharmaceuticals, Inc. We count 17 filings; the first trade dates from 28 February 2006 and the latest from 6 January 2025.

Market trades split into 5 purchases (€163k) and 2 sales (€1.4M). On balance, insiders were net sellers of €1.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants and 2 option exercises. In 2025 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €22k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 8 January 2025, the filings show an open-market purchase worth €49k in Acurx Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.